Induction of apoptosis by recombinant soluble human TRAIL in Jurkat cells.
- Author:
Gen-Hong YAO
1
;
Li-Jun LING
;
Jian-Feng LUAN
;
Dong YE
;
Pei-Yuan ZHU
;
Qian-Hong LEI
Author Information
- Publication Type:Journal Article
- MeSH: Apoptosis; drug effects; Base Sequence; DNA Primers; Electrophoresis, Agar Gel; Fluorescence; Humans; Jurkat Cells; Membrane Potentials; Recombinant Proteins; pharmacology; Reverse Transcriptase Polymerase Chain Reaction; Solubility; TNF-Related Apoptosis-Inducing Ligand; pharmacology
- From: Biomedical and Environmental Sciences 2007;20(6):470-477
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo investigate the therapeutic potential of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, and to analyze TRAIL-induced apoptosis in Jurkat cells.
METHODSExpression of TRAIL receptors (DR4 and DR5) was detected by reverse transcriptase-polymerase chain reaction (RT-PCR). Cytotoxic effects were determined by colony formation assay and a cell counting kit. The effects of recombinant TRAIL on apoptosis of Jurkat cells were determined by DNA fragmentation (DNA ladder) and PI staining. Changes in mitochondrial membrane potential were detected with JC-1 fluorescence.
RESULTSTRAIL inhibited the proliferation and induced internucleosomal DNA fragmentation (characteristic of apoptosis) and loss of mitochondrial membrane potential.
CONCLUSIONRecombinant soluble TRAIL can be used as a therapy for cancer.
